U.S., Aug. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07108998) titled 'Study of Epcoritamab as a Consolidation Therapy in CLL/SLL' on July 21.
Brief Summary: This is a phase 2 study of Epcoritamab as a consolidation therapy for 2nd generation BTKi +/- Obinutuzumab in CLL/SLL patients or patients with variants of this.
Study Start Date: Aug. 01
Study Type: INTERVENTIONAL
Condition:
CLL/SLL
CLL
SLL
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma Variant
Chronic Lymphocytic Leukemia Variants
Intervention:
DRUG: Epcoritamab
Epcoritamab is the investigational product under study in combination with SOC drugs in this protocol. During C1, epcoritamab will be initiated ...